Loading publications…
The last 5 uploaded publications
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
Miguel Vizoso, Humberto J. Ferreira, Paula López-Serra, F. Javier Carmona, Anna Martínez‐Cardús, María Romina Girotti, Alberto Villanueva, Sònia Guil, Cátia Moutinho, Julia Liz, Anna Portela, Holger Heyn, Sebastián Morán, August Vidal, María Martínez‐Iniesta, José Luís Manzano, María Teresa Fernández‐Figueras, Elena Élez, Eva Muñoz‐Couselo, Rafael Botella‐Estrada, Alfonso Berrocal, Fredrik Pontén, Joost van den Oord, William M. Gallagher, Dennie T. Frederick, Keith T. Flaherty, Ultan McDermott, Paul Lorigan, Richard Marais, Manel Esteller (2015). Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. , 21(7), DOI: https://doi.org/10.1038/nm.3863.
Article73 days agoFigure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Preprint61 days agoPhase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma
Eva Muñoz‐Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth I. Buchbinder, Mario Sznol, Hans Prenen, А. А. Феденко, Mohammed Milhem, Ana Arance, Jean‐Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Alice Martin, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Anton Kraxner, Nino Keshelava, Oliver Bechter (2025). Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. , DOI: https://doi.org/10.1158/2767-9764.crc-24-0601.
Article61 days agoTable 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221270.
Preprint61 days agoTable 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221267.
Preprint61 days ago